Navigation Links
Sanofi-aventis Announces Second Quarter 2009 Results
Date:7/29/2009

AR((R)) injection pen. The product reported strong growth across all three regions: 28.7% in the United States (to euro 495 million), 14.6% in Europe (to euro 195 million) and 42.9% in the Other Countries region (to euro 102 million). First-half net sales of Lantus((R)) were up 26.6% at euro 1,539 million.

In June 2009, sanofi-aventis announced that it had acquired the Diabel manufacturing site in Frankfurt from Pfizer for euro 30 million. This site is one of the world's largest and most modern insulin production facilities, and will increase our insulin production capability.

On June 26, 2009, four analyses of patient registries based on retrospective follow-up of people with diabetes were published online by Diabetologia. These analyses clearly show that no definitive conclusions can be drawn regarding a possible causal relationship between Lantus((R)) and an increase in the risk of cancer, as the authors of the study point out. Clinical studies, which represent the gold standard of evidence, do not indicate an association between insulin glargine and cancer.

Patient safety being the primary concern of sanofi-aventis, the company commissioned a board of international specialists in endocrinology, oncology and epidemiology to assess these analyses of registries. On July 15, this board issued an expert statement which concluded that the four studies had significant methodological limitations and shortcomings, and provided inconsistent and inconclusive results. This official statement from fourteen international experts follows recent comments on this issue made by healthcare authorities around the world, such as the EMEA and the FDA, and by patient associations and scientific bodies like the ADA, the AACE and the IDF, cautioning against any misinterpretation of or over-reaction to these data.

On July 6, 2009 sanofi-aventis announced the results of a 5-year study of Lantus(
'/>"/>

SOURCE sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

Related biology technology :

1. Sanofi-aventis Announces Settlement of Average Wholesale Price Civil Suits With the U.S. Department of Justice Relating to Anzemet(R)
2. Shareholder Class Action Filed Against Sanofi-Aventis by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
3. Sanofi-aventis SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award
4. ThalesNano Inc. and sanofi-aventis R&D Collaborate on Continuous Process Chemistry in Order to Dramatically Reduce Drug Realization Time
5. RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster
6. AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
7. BioWa Announces License of POTELLIGENT(R) Technology to sanofi-aventis
8. Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment
9. Sanofi-aventis U.S. Announces Settlement of Medicaid Best Price Investigation
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... observed tiny quantum vortices in cold droplets of liquid ... that the exotic vortices arrange themselves as densely ... time that the quantum vortices, which have already been ... superfluid helium, have been detected in nanodroplets. "The experiment ... the University of Southern California, one of the experiment,s ...
(Date:8/21/2014)... Emmetsburg, IA (PRWEB) August 21, 2014 ... Project LIBERTY Opening , The Court of His Majesty ... King will attend the Grand Opening of POET-DSM Advanced ... on Wednesday, Sept. 3. , The King will take ... formal opening activity, scheduled for 11 a.m.-12:20 p.m. and ...
(Date:8/21/2014)... , Aug. 21, 2014  Decision Resources Group ... Brazil and Mexico ... of several newly approved agents, the anticipated label ... and the launch of emerging biologics will substantially ... particular, the emerging IL-5 inhibitors will introduce a ...
(Date:8/21/2014)... -- China Cord Blood Corporation (NYSE: CO ) ... results for the first quarter of fiscal year 2015 ... the US.  The Company will host ... August 29, 2014 to discuss its financial performance and ... followed by a question and answer session.  Interested parties ...
Breaking Biology Technology:Scientists observe quantum vortices in cold helium droplets 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 3Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2
... , SAN CARLOS, Calif., Sept. 21 Nektar Therapeutics ... call to discuss today,s announcement of a new partnership for NKTR-118 and NKTR-119. ... Time (PT). , , The live audio-only Webcast of the ... home page of Nektar,s website: http://www.nektar.com . The web broadcast ...
... , LONDON and SAN CARLOS, ... announced today that they have entered into an exclusive worldwide ... stage investigational product being evaluated for the treatment of opioid-induced ... is intended to deliver products for the treatment of pain ...
... FreezerPro ... and Liquid Nitrogen Tank samples and efficiently manage data of any kind associated with ... ... of FreezerPro 2010, Frozen sample inventory and information management system (FSIIMS). FreezerPro 2010 is ...
Cached Biology Technology:Nektar Therapeutics to Host Conference Call to Discuss Today's Announcement of a New Partnership for NKTR-118 and NKTR-119 2AstraZeneca and Nektar Sign Worldwide Agreement for Nektar Drug Development Programmes -- NKTR-118 and NKTR-119 -- to Address Opioid-Induced Constipation 2AstraZeneca and Nektar Sign Worldwide Agreement for Nektar Drug Development Programmes -- NKTR-118 and NKTR-119 -- to Address Opioid-Induced Constipation 3AstraZeneca and Nektar Sign Worldwide Agreement for Nektar Drug Development Programmes -- NKTR-118 and NKTR-119 -- to Address Opioid-Induced Constipation 4AstraZeneca and Nektar Sign Worldwide Agreement for Nektar Drug Development Programmes -- NKTR-118 and NKTR-119 -- to Address Opioid-Induced Constipation 5RURO Inc. Today Announced the Release of FreezerPro 2010, Frozen Sample Inventory and Information Management System 2
(Date:8/20/2014)... WORCESTER, MA Using population-based screening outcomes of approximately ... states, including four researchers at the University of Massachusetts ... combined immunodeficiency (SCID) can be successfully implemented across public ... programs published in the Aug. 20 issue of the ... JAMA ) showed the rate of SCID in newborns ...
(Date:8/20/2014)... have discovered that acral melanomas the rare type of ... are genetically distinct from other more common types of skin ... the journal Pigment Cell & Melanoma Research . , ... soles of the feet, nail-beds and other hairless parts of ... not caused by UV damage from the sun. , The ...
(Date:8/20/2014)... pepper causes a burning spiciness that is irresistible to ... pepper,s effect are using their findings to develop a ... can be caused by inflammation or other problems. They ... tested in clinical trials, in ACS, Journal of ... that decades ago, scientists had pegged a compound called ...
Breaking Biology News(10 mins):Newborn screening expansion offers early diagnosis and treatment to infants with SCID 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 3Scientists learn more about rare skin cancer that killed Bob Marley 2
... that despite the large number of cancer-causing genes already ... Dana-Farber Cancer Institute have linked a previously unsuspected gene, ... role in cancer was made possible by new tools ... authors of the new study. As these tools are ...
... investigator Gary Ruvkun, PhD, is one of three co-recipients of ... by the Albert and Mary Lasker Foundation, the Lasker Awards ... and many Lasker recipients have gone on to win the ... on Friday, Sept. 26. Ruvkun and his co-recipients ...
... Ralph Regula (R-OH) will be presented with the ... Reception on Monday evening, September 15, 2008. They ... the United States Geological Survey (USGS). Representative Dicks ... Interior, Environment and Related Agencies and Representative Ralph ...
Cached Biology News:Researchers identify cancer-causing gene in many colon cancers 2MGH researcher Gary Ruvkun named a co-recipient of the Lasker Award 2MGH researcher Gary Ruvkun named a co-recipient of the Lasker Award 3USGS Coalition to honor Reps. Dicks, Regula with Leadership Award 2
Antibodies were affinity purified using epitopes specific to QKI immobilized on solid support....
Direct ELISA Assay Diluent, 100 mL...
Assay Diluent, 10 L...
Assay Diluent Trial Pack, 4 x 100 mL...
Biology Products: